Susquehanna International Group
CNSP icon

Susquehanna International Group’s CNS Pharmaceuticals CNSP Stock Holding History

Susquehanna International Group’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed -$24K – 12451
2023
Q3 		$24K Buy
+1
New +$54.5K ﹤0.01% 11557
2022
Q1 		– Hold
0
– -$8K – 13081
2021
Q4 		– Hold
0
– – – 12952

Other funds holding CNSP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FWA
FSM Wealth Advisors Cleveland, Ohio $939M AUM 22.84% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Susquehanna International Group's CNSP Position: Q4 2023 in Review

Susquehanna International Group sold out of CNS Pharmaceuticals (CNSP) in Q4 2023, closing a stake of 1 share — an estimated $24K sold.

Susquehanna International Group first reported a position in CNSP in Q3 2023 and held it in 1 quarter. The position peaked at $24K in Q3 2023. 6 funds tracked by Wall St. Rank hold CNSP as of Q4 2023.

  • Susquehanna International Group reported no remaining CNS Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Susquehanna International Group sold 1 CNS Pharmaceuticals share in Q4 2023, an estimated $24K.
  • Susquehanna International Group first reported a position in CNS Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Susquehanna International Group's CNS Pharmaceuticals position peaked at $24K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q4 2023.

Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.